Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson’s disease in which a patient’s stem ...

CERo Therapeutics (CERO) announces the execution of an agreement with contract research organization CellCarta to manage translational assays ...

Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical trial for ST-002, a novel drug candidate for patients ...

The European Medicines Agency and Belgium’s Federal Agency for Medicines and Health Products have approved a Phase 2 challenge study on EV25, an antiviral therapeutic from Eradivir. The approval ...

Monroe Biomedical Research (MBR), a dedicated clinical trial site, is growing its footprint to enhance early-phase clinical trials and attract more research opportunities to North Carolina.

LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.

Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treatment for chronic inflammation associated ...